Full Press Release Details
Announces Receipt of Nasdaq Notice of Bid Price Deficiency
LAKE CITY, August 19, 2016 - Amedica Corporation (Nasdaq:AMDA), a company that develops and commercializes silicon nitride
ceramics as a biomaterial platform, announced today that on August 17, 2016, the Company received a letter from the Nasdaq Listings
Qualifications department of the Nasdaq Capital Market ("Nasdaq") notifying the Company that the minimum bid price per
share for its common stock was below $1.00 for a period of thirty (30) consecutive business days and that the Company did not
meet the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2).
Nasdaq notification letter does not result in the immediate delisting of the Company's common stock, and the stock will
continue to trade uninterrupted under the symbol "AMDA." Amedica management intends to resolve the situation to allow
for continued listing on the Nasdaq Capital Market.
Company has a compliance period of 180 calendar days, or until February 13, 2017, to regain compliance with Nasdaq's minimum bid
price requirement. If at any time during the 180-day compliance period, the closing bid price per share of the Company's common
stock is at least $1.00 for a minimum of 10 consecutive business days, Nasdaq will provide the Company a written confirmation
of compliance and the matter will be closed. In the event the Company does not regain compliance with Rule 5550(a)(2) within this
compliance period, it may be eligible for additional time to regain compliance. To qualify for the additional time, the Company
will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing
standards, with the exception of the minimum bid price requirement, and will need to provide written notice of its intention to
cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. If the Nasdaq staff
concludes that the Company will not be able to cure the deficiency, or if the Company determines not to submit the required materials
or make the required representations, the Company's common stock will be subject to delisting by Nasdaq.
is focused on the development and application of interbody implants manufactured with medical-grade silicon nitride ceramic. Amedica
markets spinal fusion products and is developing a new generation of wear- and corrosion-resistant implant components for hip
and knee arthroplasty as well as dental applications. The Company's products are manufactured in its ISO 13485 certified
manufacturing facility and through its partnership with Kyocera, one of the world's largest ceramic manufacturers. Amedica's FDA-cleared
and CE-marked spine products are currently marketed in the U.S. and select markets in Europe and South America through its distributor
network and its growing OEM and private label partnerships.
more information on Amedica or its silicon nitride material platform, please visit www.amedica.com.
press release contains statements that constitute forward-looking statements within the meaning of the Securities Act of 1933
and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements
contained in this press release include, but are not limited to, the Company's expectation that it will regain compliance
with Nasdaq listing requirements or will be eligible for additional time to regain such compliance. Factors that could cause actual
results to differ materially from those contemplated within this press release can be found in Amedica's Risk Factors disclosure
in its Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 23, 2016, and in Amedica's
other filings with the SEC. Amedica disclaims any obligation to update any forward-looking statements.